Estrogen receptor: Is it predictive for response to cytotoxic as well as hormonal therapy?

Breast Cancer Research and Treatment

Volumn 127, Issue 2, 2011, Pages 587-588

  Pritchard, Kathleen I ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BIOLOGICAL MARKER; CELL PROTEIN; CYTOSOL PROTEIN; ESTROGEN RECEPTOR; PREDNISONE; TAMOXIFEN; UNCLASSIFIED DRUG;

BINDING ASSAY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; DRUG CYTOTOXICITY; HUMAN; LIGAND BINDING; MEASUREMENT; NOTE; PREDICTION; PREMENOPAUSE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BIOLOGICAL MARKERS; BREAST NEOPLASMS; FEMALE; HUMANS; RECEPTORS, ESTROGEN;

EID: 79958222255     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0325-1     Document Type: Note

References (7)

1. M Bonetti RD Gelber 2000 A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data Stat Med 19 2595 2609 10.1002/1097-0258(20001015)19:19<2595::AID-SIM562>3.0.CO;2-M 10986536 10.1002/1097-0258(20001015)19:19<2595::AID-SIM562>3.0.CO;2-M 1:STN:280:DC%2BD3M7htFOjsA%3D%3D
2. M Bonetti RD Gelber 2004 Patterns of treatment effects in subsets of patients in clinical trials Biostatistics 5 465 481 10.1093/biostatistics/kxh002 15208206 10.1093/biostatistics/kxh002 (Pubitemid 41180219)
3. MM Regan RD Gelber For the International Breast Cancer Study Group 2006 Predicting response to systemic treatments; learning from the past to plan for the future Breast 14 582 593 10.1016/j.breast.2005.08.021 10.1016/j.breast.2005. 08.021 (Pubitemid 41683584)
4. MM Regan RD Gelber 2007 Using clinical trial data to tailor adjuvant treatments for individual patients Breast 16 98 104 10.1016/j.breast.2007.07.016 10.1016/j.breast.2007.07.016 (Pubitemid 350028560)
5. DA Berry C Cirrincione IC Henderson, et al. 2006 Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer JAMA 295 1658 1667 10.1001/jama.295.14.1658 16609087 10.1001/jama.295.14. 1658 1:CAS:528:DC%2BD28XjsVeqs7k%3D
6. IC Henderson DA Berry GD Demetri, et al. 2003 Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer J Clin Oncol 21 976 983 10.1200/JCO.2003.02.063 12637460 10.1200/JCO.2003.02.063 1:CAS:528:DC%2BD2cXpsVGqs7c%3D (Pubitemid 46594124)
7. M Citron D Berry C Cirrincione, et al. 2003 Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/cancer and leukemia group B Trial 9741 J Clin Oncol 21 1 9 10.1200/JCO.2003.09.081 10.1200/JCO.2003.09.081 (Pubitemid 46594092)